Custom Search

News

Tuesday 01 April 2003

Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child.

By: Bueno J, Ramil C, Somoza I, Sanchez-Galindo A, Solar A, Arnal F, Alvarez A, Sanchez-Mozo P, Gomez M.

Pediatr Transplant 2003 Apr;7(2):153-6

Rituximab, a monoclonal antibody directed against the B-cell specific CD20 antigen has been used with success in post-transplant lymphoproliferative disorder (PTLD) of B-cell phenotype. However, the use of such drug in children with liver transplantation and PTLD is very limited. We report a 2-yr-old liver transplant recipient with monomorphic non-Hodgkin lymphoma of B-cell origin. The lymphoma did not respond to immunosuppression withdrawal, with a subsequent allograft rejection. Despite resumption of immunosuppression and rejection treatment, the lymphoma was successfully treated with rituximab.

Use of this site is subject to the following terms of use